MedTrace Logo

Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease

NCT01187992 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2010-08-25

No results posted yet for this study

Summary

This study was designed to test the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse coronary artery disease (CAD) not amenable to any form of mechanical revascularisation.

Conditions

Interventions

DRUG

Atorvastatin

80 mg/day

Sponsors & Collaborators

  • Associazione Nazionale Medici Cardiologi Ospedalieri

    collaborator OTHER

  • San Filippo Neri General Hospital

    lead OTHER

Principal Investigators

  • Furio Colivicchi, MD · Clinical Quality Mangement Unit, San Filippo Neri Hospital, Rome, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2007-03-31
Completion
2007-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01187992 on ClinicalTrials.gov